Genetic evidence that nitric oxide modulates homocysteine -: The NOS3 894TT genotype is a risk factor for hyperhomocystenemia

被引:49
作者
Brown, KS
Kluijtmans, LAJ
Young, IS
Woodside, J
Yarnell, JWG
McMaster, D
Murray, L
Evans, AE
Boreham, CA
McNulty, H
Strain, JJ
Mitchell, LE
Whitehead, AS
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Ctr Pharmacogenet, Philadelphia, PA 19104 USA
[3] Univ Med Ctr Nijmegen, Nijmegen, Netherlands
[4] Queens Univ Belfast, Cardiovasc Res Ctr, Belfast, Antrim, North Ireland
[5] Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland
[6] Univ Ulster, No Ireland Ctr Diet & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland
[7] Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA
关键词
nitric oxide; nitric oxide synthase; hyperhomocystenemia; 5,10-methylenetetrahydrofolate reductase; smoking;
D O I
10.1161/01.ATV.0000071348.70527.F4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Mild hyperhomocystenemia is an independent, graded risk factor for cardiovascular disease. Genetic determinants of hyperhomocystenemia include functional polymorphisms in several folate/homocysteine metabolic enzymes. Nitric oxide may also modulate plasma homocysteine (tHcy) concentrations, either by direct inhibition of methionine synthase or via an indirect effect on folate catabolism. Methods and Results-The hypothesis that the endothelial nitric oxide synthase (NOS3) G894T polymorphism is a genetic determinant of tHcy concentrations was tested in 2 independent healthy adult populations. In both populations, NOS3 genotype was significantly associated with tHcy concentrations in nonsmokers with low folate (P = 0.03 for each). Models were constructed to adjust for known determinants of tHcy concentrations and test for interactions between NOS3 genotype and these determinants in nonsmokers from each population. NOS3 genotype remained a significant determinant of tHcy concentrations after adjustment. Interactions between NOS3 genotype and serum folate were significant in both populations, and the interaction between NOS3 genotype and MTHFR C677T genotype was significant in the larger population. Conclusions-These data indicate that the NOS3 894TT genotype is a risk factor for elevated tHcy in healthy nonsmoking adults with low serum folate and supports the hypothesis that nitric oxide modulates homocysteine through an effect on folate catabolism.
引用
收藏
页码:1014 / 1020
页数:7
相关论文
共 30 条
  • [1] Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
    Al Suwaidi, J
    Hamasaki, S
    Higano, ST
    Nishimura, RA
    Holmes, DR
    Lerman, A
    [J]. CIRCULATION, 2000, 101 (09) : 948 - 954
  • [2] Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation
    Barua, RS
    Ambrose, JA
    Eales-Reynolds, LJ
    DeVoe, MC
    Zervas, JG
    Saha, DC
    [J]. CIRCULATION, 2001, 104 (16) : 1905 - 1910
  • [3] Boreham C, 1999, PUBLIC HEALTH, V113, P7, DOI 10.1016/S0033-3506(99)00106-7
  • [4] Physical activity, sports participation, and risk factors in adolescents
    Boreham, CA
    Twisk, J
    Savage, MJ
    Cran, GW
    Strain, JJ
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1997, 29 (06) : 788 - 793
  • [5] Combined effects of endothelial nitric oxide synthase gene polymorphism (G894T) and insulin resistance status on blood pressure and familial risk of hypertension in young adults: The Bogalusa Heart Study
    Chen, W
    Srinivasan, SR
    Elkasabany, A
    Ellsworth, DL
    Boerwinkle, E
    Berenson, GS
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (10) : 1046 - 1052
  • [6] DANESH J, 1998, J CARDIOVASC RISK, P229
  • [7] Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway
    Danishpajooh, IO
    Gudi, T
    Chen, YC
    Kharitonov, VG
    Sharma, VS
    Boss, GR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27296 - 27303
  • [8] Impaired homocysteine metabolism and atherothrombotic disease
    Durand, P
    Prost, M
    Loreau, N
    Lussier-Cacan, S
    Blache, D
    [J]. LABORATORY INVESTIGATION, 2001, 81 (05) : 645 - 672
  • [9] A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE
    FROSST, P
    BLOM, HJ
    MILOS, R
    GOYETTE, P
    SHEPPARD, CA
    MATTHEWS, RG
    BOERS, GJH
    DENHEIJER, M
    KLUIJTMANS, LAJ
    VANDENHEUVEL, LP
    ROZEN, R
    [J]. NATURE GENETICS, 1995, 10 (01) : 111 - 113
  • [10] The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations
    Gaughan, DJ
    Kluijtmans, LAJ
    Barbaux, S
    McMaster, D
    Young, IS
    Yarnell, JWG
    Evans, A
    Whitehead, AS
    [J]. ATHEROSCLEROSIS, 2001, 157 (02) : 451 - 456